Lantheus (Nasdaq: LNTH) acquires rep. Gilbert Ray Sassos, Jr. – the world of defense

Representative Gilbert Ray Sasso, D-California recently bought shares of Lantheus Holdings, Inc. (Nasdaq: LNTH). In the submission, revealed on February 11, the representative revealed that they had purchased between $ 1.001 and $ 15,000 in Lantheus shares on January 28. The trade happened in the account of the representative “150 Main Street> Bank of America”.

Representative Gilbert Ray Sassos, Jr., also recently made the following trade (s):

• Sold $ 1.001 – $ 15,000 shares on ICF International (NASDAQ: ICFI) on 2/3/2025.
• Purchased $ 15 001 – $ 50,000 shares of CACI International (NYSE: CACI) on 1/31/2025.
• Purchased $ 50 001 – $ 100,000 shares of Hawaii Electric Industries (NYSE: HE) on 1/31/2025.
• Sold $ 1 001 – $ 15,000 shares of Broadcom (NASDAQ: AVGO) on 30.01.2025.
• Purchased $ 1.001 – $ 15,000 shares of intuitive surgery (NASDAQ: ISRG) on 1/30/2025.
• Purchased $ 1 001 – $ 15,000 shares of Agios Pharmaceuticals (NASDAQ: Agio) on 29.01.2025.
• Purchased $ 1 001 – $ 15,000 shares on Springworks Therapeutics (NASDAQ: SWTX) on 29.01.2025.
• Purchased $ 1 001 – $ 15,000 in Paragon 28 shares (NYSE: FNA) on 29.01.2025.
• Purchased $ 1 001 – $ 15,000 shares from physical therapy in the US (NYSE: USPH) on 29.01.2025.
• Purchased $ 1 001 – $ 15,000 shares at Crinetics Pharmaceuticals (NASDAQ: CRNX) on 29.01.2025.

Lantheus trades with 0.2 %

Nasdaq LNTH’s shares opened at $ 82.10 on Thursday. The action has a fifty -day average price of $ 91.76 and a 200 -day average price of $ 98.13. The company has a market cap of $ 5.71 billion, a P/E ratio of 13.66 and a beta of 0.44. Lantheus Holdings, Inc. It has a 12-month minimum of $ 54.69 and a 12-month high of $ 126.89.

Hedge funds weigh on Lantheus

Several Hedge Funds have recently bought and sold business shares. Landscape Capital Management LLC increased its position in Lantheus by 312.8% in the 4th quarter. The Landscape Capital Management LLC holds 16 358 shares of the $ 1.463,000 medical equipment supplier shares after the purchase of an additional $ 12,395 shares in the last quarter. Foundry Partners LLC has raised its share in Lantheus shares by 4.5% in the fourth quarter. Foundry Partners LLC holds 3 103 shares from the shares of the $ 278,000 medical equipment supplier after the purchase of an additional 133 shares during the period. Cynosure Group LLC increased its position in Lantheus by 9.2% in the fourth quarter. The Cynosure Group LLC already holds 3.558 shares from the shares of the $ 318,000 medical equipment supplier after purchasing an additional 299 shares in the last quarter. Massachusetts Financial Services Co. MA increased its participation in Lantheus by 37.0% in the fourth quarter. Massachusetts Financial Services Co. MA now holds 323,900 shares from the shares of the Medical Equipment Provider worth $ 28,976,000 after acquiring an additional $ 87,412 shares during the period. Finally, Trexquant Investment LP acquired a new position in Lantheus in the 4th quarter worth approximately $ 7,238,000. 99.06% of the shares are owned by institutional investors and hedge funds.

Wall Street analysts predict growth

A number of analysts have recently issued reports on the company. JMP Securities confirmed the market “Market Overbur” and set a target price of $ 112.00 for Lantheus shares in a research report on Tuesday, January 14th. Stocknews.com lowered Lantheus from the Buy rating to the Rating Rating in a Thursday 21st November 21st Research note. The Goldman Sachs Group took a coverage of Lantheus in a Wednesday report, December 18th. They put a rating “Buy” and a price price of $ 143.00 per share. Finally, the Truist Financial repeated Rating and set the target price of $ 120.00 (a reduction of $ 135.00) for Lantheus shares in a Friday 8 -November research note. One stock research analyzer has evaluated the stock rating shares and seven issued a rating to buy the company. Based on MarketBeat data, the action has a consensus rating “Moderate Purchase” and an average target price of $ 131.86.

See our Lantheus Reserves Analysis

Insiders place their bets

In the related news, director James H. Traw sold 1,000 shares from the company’s shares in Wednesday, January 15. The shares were sold at an average price of $ 94.76, for a total value of $ 94,760.00. After the sale, the director now owns 33,207 shares of the company, valued at $ 3,146 695,32. Trade was a 2.92 % reduction in their ownership of the shares. The deal was announced on a legal submission to SEC, which is available through this hyperlink. Corporate internal persons have 1.50% of the company’s shares.

For the representative Cisneros

Gil Cissens (Democratic Party) is a member of the American House representing the 31st Congress County of California. He took office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election at the American House to present Central Congress County of California. He announced an application for the 2026 election.

Gill Sisharos served at the US Navy as a supply employee from 1994 to 2004. Cisneros won a bachelor’s degree in political science from George Washington University in 1994, Master’s Degree in Business Administration from Reise University and Master’s Degree in City City Degree Educational policy at Brown University in 2015. His career experience includes work as a logistics manager at Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, establishing a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as the Secretary of Defense for Personnel and Readiness.

Lantheus profile

(Get a free report)

Lantheus Holdings, INC develops, produces and commercializes the diagnostic and therapeutic products that help clinicians in the diagnosis and treatment of heart, cancer and other diseases around the world. It provides a definition of injection ultrasound enhancer used in echocardiography exams; Technelite, a generator of a nuclear medicine procedures; Xenon-133, radiopharmaceutical gas to evaluate pulmonary function; Neurolite, injection image to identify the area in the brain, where blood flow is blocked or decreased due to stroke; Cardiolite, an image agent for images marked by TC-99M, to evaluate blood flow to the heart muscle; And Pylarify, F 18-branded PSMA-PSMA PSMA PET depiction agent used for PSMA images positive urges in men with prostate cancer.

Increasing

Get news and ratings for Lantheus Daily -Enter your email address below to receive a short daily summary of the latest news and analysts for Lantheus and connected companies with the free daily newsletter of MarketBeat.com.